Article
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives - Blood Cancer Journal
Rating:
0.0
Views:
12
Likes:
1
Library:
1
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies and are often associated with a proliferative phenotype. RAS mutations harbor allele-specific structural and biochemical properties depending on the hotspot mutation, contributing to variable biological consequences.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value